Immunome Appoints Bob Lechleider, M.D., as Chief Medical Officer

– Seasoned biotechnology executive and board-certified physician in medical oncology joins executive team as Immunome advances growing pipeline of cancer therapies 

See more here


Venatorx Pharmaceuticals Awarded a Third Antibiotic BARDA Contract

Total award of up to $167 million for development of novel oral antibiotic ceftibuten-ledaborbactam etzadroxil for treatment of complicated urinary tract infection (cUTI), including pyelonephritis

See more here


Immunome and Morphimmune Announce Successful Completion of Merger with $125 Million PIPE to Develop Novel Targeted Cancer Therapies

Clay B. Siegall, Ph.D., former co-founder & CEO of Seagen, Inc., appointed as Chairman and CEO

$125 million private placement investment completed with leading institutional investors will support cash runway expected to extend into Q1 2026*

Expected to submit three investigational new drug applications (INDs) within 18 months

See more here


ImmunoGenesis Doses First Patient in Phase 1a/1b Clinical Trial of IMGS-001 in Relapsed or Refractory Advanced Solid Tumors

IMGS-001 is the first dual-specific PD-L1/PD-L2 antibody with cytotoxic function designed to treat immune-excluded cancers that are resistant to existing immunotherapies  

See more here


SIRPant Immunotherapeutics to Present Trial in Progress Poster at the Society for Immunotherapy of Cancer 38th Annual Meeting

See more here


Venatorx Pharmaceuticals to Present at IDWeek 2023

– New data to be presented from Phase 3 CERTAIN-1 study with Cefepime-Taniborbactam

– MD Anderson Cancer Center analysis of Cefepime-Taniborbactam in vitro activity against clinically significant gram-negative bacteria isolated from patients with cancer

See more here


Strados Labs Announces Pediatric Asthma Study to Validate its Wearable Device in Children with Wheeze

Strados Labs’ RESP™ Biosensor is currently being used in a clinical trial at Lurie Children’s to determine if the technology can accurately detect wheezing and other symptoms of asthma exacerbation in children.  

See more here


Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 LongTerm Study of REL-1017 in Major Depressive Disorder

Patients newly treated with REL-1017 for up to one year experienced rapid, clinically meaningful, and sustained improvements in depressive symptoms and associated functional impairment

Long-term dosing with REL-1017 was well-tolerated, with low rates of adverse events and discontinuations due to adverse events, and no new safety signals were detected

See more here


KayoThera, Inc. Nominates First-in-Class, Oral Inhibitor of the Retinoid Pathway in Genetically Defined Oncology Indications as a Development Candidate 

Unique safety profile positions KAYO-1609 as the first retinoid pathway inhibitor to enter Investigational New Drug (IND)-enabling studies

Company expects to file IND application with the U.S. Food & Drug Administration (FDA) by the end of 2024

See more here


VESTECK Scientific Advisory Board members address significant global unmet need

See more here